US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 04:32:31 Source:travelViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive
Next:The 13 style rules that every midlife woman MUST follow (and yes, beige really is banned!)
You may also like
- FDIC chairman Martin Gruenberg to step down, White House says
- Mexico protests to UN chief over Ecuador's raid on embassy
- Book on Xi's Discourses on China's Manufacturing Strength Published
- Feature: Surinamese villagers enjoy electricity supply thanks to eco
- Sienna Miller's lookalike daughter Marlowe, 11, makes her first ever red carpet appearance
- Forest fire claims three lives in Guizhou
- Washington's drug slur on Beijing slammed
- Ecuador calls OAS resolution on Mexican embassy raid "fair"
- Kevin Pillar gets 1,000th career hit in Angels' win at Texas